The function of the tumor suppressor protein p53 is modulated by post-translational events, primarily by phosphorylation. p53 is phosphorylated at multiple sites by a variety of protein kinases depending on the cellular environment. It has been suggested that serine 34 of mouse p53 is speci®cally phosphorylated by a stressactivated protein kinase in response to ultraviolet radiation. Since serine 34 is a major site of phosphorylation of mouse p53 in vivo and its speci®c protein kinase is still not de®nitively identi®ed yet, we have examined the c-Jun N-terminal kinase 1 (JNK1) activity on p53 by expressing JNK1 in 293T cells. We show here that activated JNK1 phosphorylates mouse p53 speci®cally at serine 34 in vitro, while a dominanant-negative JNK1 mutant does not phosphorylate p53. More importantly, JNK1 associates with p53 in vivo, with or without activation, con®rming that JNK1 is indeed a p53 kinase. Interestingly, activated JNK2 and JNK3 also phosphorylate serine 34 of mouse p53. Furthermore, JNK2 and JNK3 also associate with p53 in vivo, indicating that not only JNK1, but also JNK2 and JNK3 are p53 Nterminal serine 34 kinases. Phosphorylation of p53 by JNKs may play an important role in nuclear signal transduction in response to environmental stress or tumorigenic agents.
Introduction
The tumor suppressor protein p53 modulates cell proliferation and plays a crucial role in suppressing development of tumors (for reviews, see Ullrich et al., 1992; Vogelstein and Kinzler, 1992; Donehower and Bradley, 1993; Levine, 1993; Ko and Prives, 1996) . Loss of P53 suppressor suppressor function through mutation or deletion is the most common genetic change associated with a wide variety of human cancers (Hollstein et al., 1991; Levine et al., 1991) . p53 is an oligomeric phosphoprotein that binds to speci®c DNA sequences to regulate transcription of a number of cellular and viral genes and exerts both proliferative and anti-proliferative eects (for reviews, see Ullrich et al., 1992; Donehower and Bradley, 1993; Levine, 1993; Ko and Prives, 1996) . In some cells, activation of p53 leads to cell growth arrest by inhibiting cell-cycle progression at the G1/S boundary (Mercer et al., 1991; Kastan et al., 1991; Kuerbitz et al., 1992) , whereas in other cells, activation of p53 induces apoptosis (Liu et al., 1994 (Liu et al., , 1995 Symonds et al., 1994; Yang et al., 1995) . The molecular mechanisms by which p53 regulates cell growth remain largely unknown; however, post-translational modi®cations may modulate p53 conformation to produce either growth-stimulating or growth-suppressing eects.
p53 is phosphorylated at multiple sites, many of which are clustered in the N-terminal domain, whereas the others are more dispersed in the carboxy-terminal region of the molecule (for review, see . p53 can be multiply phosphorylated by a variety of protein kinases, including casein kinase I (CKI) (Milne et al., 1992) and CKII (Meek et al., 1990; Herrmann et al., 1991; Muller et al., 1993) , cyclin-dependent kinases (cdks) Bischo et al., 1990; Milner et al., 1990; Sturzbecher et al., 1990) , double-stranded DNA activated protein kinase (DNA-PK (Lees-Miller et al., 1992) , and mitogen-activated protein kinase (MAP kinase) (Milne et al., 1994) , protein kinase C (PKC) (Baudier et al., 1992; Hupp and Lane, 1994) , raf1 (Jamal and Zi, 1995) , and an SV40 large T-activated kinase (Muller and Scheidtmann, 1995) . It has been shown recently that the regulation of the DNA-binding activity of p53 is modulated by phosphorylation at individual sites (Hecker et al., 1996) . Thus, the activity of p53 might be regulated, perhaps coordinately, by a variety of signals from dierent pathways that produce dierential phosphorylation of p53. However, it remains to be elucidated which of the activities of p53 are modulated by phosphorylation. The transcriptional activation domain of p53 is located within the N-terminal 73 amino acids (Field and Jang, 1990 ) and several phosphorylation sites have been mapped within this region. Mutation of phosphorylation sites in the N-terminus of p53 leads to signi®cant loss of tumorsuppressor and transactivation functions (Mayr et al., 1995) . In mouse p53 (numbering according to Soussi et al., 1990) , serine residues 4, 6, 15 and 34 are highly phosphorylated in vivo (Wang and Eckhart, 1992) . Serine residues 4, 6 and 9 can be phosphorylated by CKI in vitro (Milne et al., 1992) , while serine residues 4 and 15 can be phosphorylated by DNA-PK in vitro (Lees-Miller et al., 1992) . The eects of p53 N-terminal phosphorylation by other protein kinases are less well characterized.
Although serine 34 is a major site of phosphorylation of mouse p53 (serine 33 of human p53) in vivo (Wang and Eckhart, 1992) , less is known about the enzymes that phosphorylate this site. It has been previously shown that ultraviolet (u.v.) irradiation of cells activates a peak of p53 serine 34 kinase in the cell lysates and the enzyme in the peak has been adequately characterized as a kinase related to the c-Jun Nterminal kinase 1 (JNK1) (Milne et al., 1995) . However, JNK1 has neither been explicitly tested for p53 phosphorylation nor examined for physical association with p53. JNKs are stress-activated protein kinases (SAPKs) which play a key role in the responses stimulated by proin¯ammatory cytokines, environmental stress, and apoptotic agents (for reviews, see Davis, 1994; Karin, 1995) . Recent studies indicate that there are 3 JNK members (JNK1 (46 kD, Derijard et al., 1994; Kyriakis et al., 1994) , JNK2 (55 kD, Kallunki et al., 1994) and JNK3 (48 kD for a1, Gupta et al., 1996) ) with 10 alternatively spliced JNK isoforms expressed in the human brain that dier in their interaction with ATF2, Elk-1 and Jun transcription factors (Gupta et al., 1996) . However, it is not clear which JNK or JNKlike protein kinases are responsible for mouse p53 serine 34 phosphorylation.
In this report, we have investigated the protein kinases which phosphorylate serine 34 of mouse p53. By direct cDNA transfection approaches, we have established that JNK1 is indeed a p53 N-terminal serine 34 kinase. Furthermore, we have shown that JNK2 and JNK3 are also p53 N-terminal serine 
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Figure 1 JNK1 phosphorylates mouse p53 at serine 34. 293T cells were transfected with an empty expression vector alone (negative control, lane 1), the indicated expression plasmid containing either JNK1 or JNK1 mutant JNK1(APF) cDNA alone or cotransfected with either HPK1 or MEKK1 cDNA (10 mg each). pVA1 plasmid (10 mg) containing adenovirus VA1 RNA gene was also included in each transfection to enhance transient protein expression. The cells were harvested 48 h after transfection. As a positive control, 293T cells transfected with JNK1 cDNA alone (lane 4) were starved for 16 h, followed by treatment with anisomycin (1 mg/ml) for 1 h. After immunoprecipitation with anti-JNK1 antiserum, JNK1 kinase activity was measured by immunocomplex kinase assays, using GST-p54(FP221) (a), GST-p53(FP274) (b) and GST-c-Jun(1 ± 193) (c) as substrates. As a control for JNK1 and JNK1 mutant expression, equal amounts of each cell lysate (200 mg) were resolved by 10% SDS ± PAGE, and immunoblotted with anti-JNK1 antiserum (d). JNK1 kinase activity was quantitated using a phosphorimager and ImageQuant software (Molecular Dynamics, Inc.) and the data are presented as arbitrary units (right panel)
p53 phosphorylation by JNKs MC-T Hu et al kinases. Since prolonged activation of JNK1 induces apoptosis (Xia et al., 1995; Chen et al., 1996; Verheij et al., 1996) , phosphorylation of serine 34 of mouse p53 by JNKs may play a role in p53-induced apoptosis. Thus, establishing the interaction between p53 and JNKs may be important for elucidating the mechanisms underlying the p53-dependent growth arrest and apoptotic pathways.
Results
Activated JNK1 phosphorylates mouse p53 speci®cally at serine 34
To investigate whether JNK1 could phosphorylate p53, we transfected JNK1 cDNA into 239T cells and prepared lysates from transfected cells, with or without anisomycin treatment. Since we have recently cloned a new functional activator of JNK1, termed hematopoietic progenitor kinase 1 (HPK1) (Hu et al., 1996) , we cotransfected JNK1 cDNA with HPK1 cDNA into 293T cells for a comparison. After immunoprecipitation with anti-JNK1 antibody, the JNK1 kinase activity was determined by an immunocomplex kinase assay, using GSTp53(FP221), GST-p53(FP274) and as substrates. The GST-p53 fusion protein (FP221) contains the N-terminal 85 amino acids of mouse p53, and the GST-p53 mutant fusion protein (FP274) contains the same region of mouse p53 with serine 34 mutated to alanine (Milne et al., 1995) . The immunocomplex kinase assay detected strong phosphorylation of GST-p53(FP221) by activated JNK1 (Figure 1a , lanes 4, 5) but very low level phosphorylation of GST-p53(FP274) (Figure 1b) . As a positive control, activated JNK1 strongly phosphorylated its physiological substrate GST-c-Jun(1 ± 193) ( Figure 1c ). As negative controls, vector or HPK1 alone was transfected into 293T cells (Figure 1, lanes 1, 2) , and no or very little JNK1 activity was detected.
To show that JNK1 was truly the only kinase present in the immunocomplexes responsible for mouse p53 serine 34 phosphorylation, we used the dominantnegative JNK1 mutant (JNK1(APF)) and tested the ability of this mutant to phosphorylate the substrates GST-p53(FP221), , and GST-cJun(1 ± 193). Since MEKK1 has been shown to be a potent activator of JNK1 (Minden et al., 1994; Yan et al., 1994; Derijard et al., 1995) , we cotransfected a MEKK1 expression plasmid with JNK1 cDNA or JNK1(APF) mutant cDNA into 293T cells. JNK1 and JNK1(APF) kinase activities were determined by immunocomplex kinase assays using anti-JNK1 antibody. We found that the MEKK1-activated dominantnegative JNK1(APF) mutant did not phosphorylate GST-p53(FP221) or GSTp53(FP274) (Figure 1, lane 8) , whereas the MEKK1-activated wild-type JNK1 phosphorylated GST-p53(FP221) and GST-c-Jun(1 ± 193) strongly as expected (Figure 1, lane 6) . Similarly, the anisomycin-induced dominant-negative JNK1(APF) mutant did not phosphorylate GST-p53(FP221) (data not shown), indicating that MEKK1 or anisomycin does not activate other kinases which may associate with JNK1 and phosphorylate GST-p53(FP221). As a control for JNK1 and JNK1(APF) mutant expression, equal amounts of each cell lysate were resolved by SDS-PAGE, immunoblotted with anti-JNK1 antibody. The data showed similar levels of JNK1 and JNK(APF) mutant expression in corresponding samples (Figure 1d ). These results demonstrate that phosphorylation of mouse p53 at serine 34 is solely due to activated JNK1 and not related kinase in the immunocomplexes.
To determine whether the observed JNK1 activity was speci®cally from JNK1 and not from other JNK1-associated kinases or anti-JNK1 antibody cross-reacted kinases, we performed in-gel kinase assays with either GST-p53(FP221) or GSTp53(FP274) as a substrate. After immunoprecipitation with anti-JNK1 antibody, the in-gel kinase assay showed that GST-p53(FP221) was speci®cally phosphorylated by a single kinase with the apparent molecular mass of JNK1 (46 kD) (Figure 2a ). This demonstrated that the kinase activity was from JNK1 and not from other kinases that may have been associated with the JNK1 complex. In contrast, the in-gel kinase assay with GST-p53(FP274) as a substrate did not detect JNK1 activity, indicating that JNK1 phosporylates mouse p53 speci®cally at serine 34 ( Figure 2b ). As a control for JNK1 expression, we demonstrated similar levels of JNK1 protein expression in each JNK1-transfected cell lysate ( Figure 2c ). Figure 2 Serine 34 of mouse p53 was phosphorylated speci®cally by JNK1. the same cell lysates from the transfected 293T cells as described in Figure 1 legend were immunoprecipitated with either anti-HPK1 or anti-JNK1 antiserum, JNK1 kinase activity was determined by in-gel kinase assays, using GST-p53(FP221). (a), and GST-p53(FP274) (b) as substrates. As a control for JNK1 expression, equal amounts of each cell lysate (200 mg) were resolved by 10% SDS ± PAGE, and immunoblotted with anti-JNK1 antiserum (c).
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To con®rm that serine 34 was a major site of phosphorylation of mouse p53 by JNK1, we isolated the 32 P-labeled bands of GST-p53(FP221) and GSTp53(FP274) from the polyacrylamide gels of the immunocomplex kinase assays as described above (Figure 1a and b) and performed phosphoamino acid analysis (Boyle et al., 1991) . As expected, phosphoamino acid analysis of in vitro phosphorylated GSTp53(FP221) detected P-Ser predominantly (Figure 3a) , while in vitro phosphorylated GST-p53(FP274) did not show detectable P-Ser (Figure 3b ). These results con®rm serine 34 as a primary site of phosphorylation of mouse p53 by JNK1.
JNK1 associates with p53 in vivo, with or without activation
Although activated JNK1 phosphorylated p53 in vitro, the relationship between JNK1 and p53 in vivo is still not clear. Hence, we wished to examine whether JNK1 could physically associate with p53 in vivo. The rationale is that if these two proteins are associated together in vivo, one should be able to immunoprecipitate both proteins with either anti-JNK1 or anti-p53 antibodies and verify their association by double-cycle immunoprecipitations. We contransfected JNK1 cDNA with a full-length p53 cDNA, with or without MEKK1, into 293T cells and followed their interaction by 35 S-methionine and 35 S-cysteine labeling. As shown in Figure 4a , anti-JNK1 antibody immunoprecipitated speci®cally JNK1 together with the full-length p53 which was veri®ed by the second immunoprecipitation using an anti-p53 monoclonal antibody. These results indicate that JNK1 associated with p53 speci®cally in vivo. Interestingly, the association of JNK1 and p53 did not depend on the JNK1 activation state (lanes 2 and 3). As negative controls, transfection of p53 with an unrelated protein c-Rel (75 kD) (lane 4) or transfection of JNK1 alone (lane 1) did not show p53 interaction with c-Rel or JNK1, indicating that p53/ JNK1 association is not an artifact of over-expression of p53 or JNK1. The relative expression level of p53 or JNK1 in each transfectant was con®rmed by one cycle immunoprecipitation with either anti-p53 monoclonal antibody (Figure 4b ) or anti-JNK1 antibody ( Figure  4c ). Taken together, our data establish than JNK1 is indeed a p53 serine 34 kinase.
JNK2 and JNK3 are also p53 serine 34 kinases
Another member of the JNK family, termed JNK2, shares strong homology with JNK1 but binds c-Jun about 25 times more eciently than JNK1 (Kallunki et al., 1994) . We decided to examine whether JNK2 (55-kD) could also phosphorylate p53 at the same site. Accordingly, we transfected a N-terminal HA-tagged JNK2 (HA-JNK2) cDNA into 293T cells and prepared lysates from transfected cells, with or without anisomycin treatment. Since we did not know whether HPK1 could activate JNK2, we cotransfected HA-JNK2 cDNA with HPK1 or MEKK1 cDNA into 293T cells for a comparison. After immunoprecipitation with anti-HA antibody, the JNK2 kinase activity was determined by an immunocomplex kinase assay, using GST-p53(FP221), GSTp53(FP274) , and GST-c-Jun(1 ± 193) as substrates. The immunocomplex kinase assay detected strong phosphorylation of GST±p53(FP221) by activated JNK2 (Figure 5a , lanes 3 ± 5) but very little phosphorylation of GST-p53(FP274) (Figure 5b , lanes 3 ± 5). As a positive control, activated JNK2 strongly phosphorylated its physiological substrate GST-c-Jun (1 ± 193) ( Figure 5c , lanes 3 ± 5). As a negative control, vector alone was transfected into 293T cells and no JNK2 kinase activity was detected (lane 1). As a control for JNK2 expression, an equal amount of each cell lysate was resolved by SDS ± PAGE, immunoblotted with anti-HA antibody, and showed a similar level of JNK2 protein expression in corresponding samples (Figure 5d . These results suggest that JNK2 is another p53 N-terminal serine 34 kinase. In addition, we showed that HPK1 could also activate JNK2 albeit not as potently as MEKK1. Very recently, a new member of the JNK family, called JNK3, has been isolated from a human brain cDNA library (ten alternatively spliced JNK isoforms derived from 3 JNK genes) (Gupta et al., 1996) . Although the sequences and regulation of these isoforms are very similar, they dier in their interaction with ATF2, Elk-1 and Jun transcription factors (Gupta et al., 1996) . Since JNK1 and JNK2 phosphorylate p53 speci®cally at N-terminal serine 34 as described above, we tested whether JNK3 could act on p53 as well. In the same manner as described for JNK2, we transfected a N-terminal HA-tagged JNK3 (HA-JNK3) cDNA alone or contransfected HA-JNK3 cDNA with HPK1 or MEKK1 cDNA into 293T cells, and determined the JNK3 kinase activity by an immunocomplex kinase assay, using GSTp53(FP221), GST-p53(FP274), and GST-c-Jun(1 ± 193) as substrates. Surprisingly, we could not detect signi®cant JNK3 kinase activity on GST-c-Jun(1 ± 193) nor HA-JNK3 protein in the cell lysates. After we repeated this transfection experiment three times, we constructed a C-terminal FLAG-tagged JNK3 (JNK3-FLAG) cDNA expression vector. JNK3-FLAG cDNA alone or JNK3-FLAG cDNA with HPK1 or MEKK1 cDNA were cotransfected into 293T cells and the JNK3 kinase activity was determined by an immunocomplex kinase assay, using anti-FLAG M2 monoclona antibody. Interestingly, the immunocomplex kinase assay detected strong phosphorylation of GST-p53(FP221) (Figure 5e , lanes 3 ± 5) and (Figure 5g , lanes 3 ± 5) by activated JNK3 but very little phosphorylation of GST-p53(FP274) (Figure 5f , lanes 3 ± 5). As a negative control, vector alone was transfected into 293T cells and no JNK3 kinase activity was detected (lane 1). As a control for JNK3 expression, equal amounts of each cell lysate were resolved by SDS ± PAGE, immunoblotted with anti-FLAG M2 monoclonal antibody. The results showed signi®cant JNK3 protein expression in corresponding samples with some variations (Figure  5h ). These results suggest that JNK3 is also a p53 Nterminal serine 34 kinase. Moreover, activated JNK1, HA-JNK2 and JNK3-FLAG also phosphorylated the full-length p53 (GST-p53) protein in an immunocomplex kinase assay (data not shown). However, we did not know exactly why the N-terminal HA-tagged JNK3 (HA-JNK3) was not functional. Perhaps the Nterminal HA sequence interfered with the structure or expression of HA-JNK3. Interestingly, similar to JNK1 and JNK2, JNK3 could be activated strongly by anisomycin, MEKK1 and HPK1, suggesting that all three JNK members are regulated by the same signaling pathway. Although activated JNK2 and JNK3 also phosphorylated p53 in vitro, we wished to examine further if JNK2 and JNK3 could physically associate with p53 in vivo. To analyse JNK/p53 interactions, we decided to immunoprecipitate both proteins with either anti-HA (for HA-JNK2) or anti-FLAG (for JNK3-FLAG) antibodies and detect their association by Western blot analysis using anti-p53 antibody. Accordingly, we cotransfected a full-length p53 cDNA with either HA-JNK2 or JNK3-FLAG cDNA into 293T cells and prepared lysates from transfected cells. Since JNK1 associated with p53 in vivo as described above, we cotransfected p53 cDNA with JNK1 cDNA into 293T cells as a positive control. As expected, anti-JNK1 antibody immunoprecipitated speci®cally JNK1 together with the full-length p53 which was veri®ed by Western blot analysis using the peroxidase-conjugated anti-p53 monoclonal antibody (Figure 6a, lane 1) . Similarly anti-HA and anti-FLAG monoclonal antibodies immunoprecipitated speci®cally JNK2 and JNK3 together with the full-length p53, respectively (Figure 6a, lanes 3 and 5) . These results indicate that JNK2 and JNK3 associated with p53 speci®cally in vivo. Furthermore, p53/JNK1, p53/JNK2 and p53/ JNK3 associations are approximately at the same level, suggesting that the binding anities of JNK1, JNK2 and JNK3 to p53 are about the same. As negative controls, transfection of p53 with an unrelated protein c-Rel (75 kD 
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Figure 5 JNK2 and JNK3 phosphorylate serine 34 of mouse p53. 293T cells were transfected with an empty expression vector alone (negative control, lane 1), the indicated expression plasmid containing either HA-JNK2 or JNK3-FLAG cDNA alone or cotransfected with either HPK1 or MEKK1 cDNA (10 mg each). pVA1 plasmid (10 mg) containing adnovirus VA1 RNA gene was also included in each transfection to enhance transient protein expression. The cells were harvested 48 h after transfection. As positive controls, 293T cells transfected with plasmids containing either HA-JNK2 or JNK3-FLAG cDNA alone were starved for 16 h, followed by treatment with anisomycin (1 mg/ml) for 1 h. After immunoprecipitation with anti-HA mAb, JNK2 kinase activity was determined by immunocomplex kinase assays, using GST-p53(FP221) (a), GST-p53(FP274) (b) and GST-c-Jun(1 ± 193) (c) as substrates. As a control for JNK1 expression, equal amounts of each cell lysate (200 mg) were resolved by 10% SDS ± PAGE, and immunoblotted with anti-HA mAb (d). Similarly, after immunoprecipitation with anti-FLAG M2 monoclonal antibody, JNK3 kinase activity was measured by immunocomplex kinase assays, using GST-p53(FP221) (e), GST-p53(FP274) (f), and GST-c-Jun(1 ± 193) (g) as substrates. As a control for JNK3 expression, equal amounts of each cell lysate (200 mg) were resolved by 10% SDS-PAGE, and immunoblotted with anti-FLAG M2 monoclonal antibody (h). JNK2 and JNK3 kinase activities were quantitated using a phosphorimager and ImageQuant software (Molecular Dynamics, Inc.) and the data are presented as arbitrary units (right panel)
Discussion
Although many of the phosphorylation sites of p53 have been identi®ed and their protein kinases characterized, little is known about the kinase which targets serine 34 of mouse p53. In this report, we have investigated the kinase activity of JNK1 on p53 by transfecting JNK1 cDNA into 293T cells with or without activators. Furthermore, we have examined the direct physical interaction between p53 and JNK1 in vivo. Our data verify that JNK1 is indeed a p53 serine 34 kinase. However, it has been recently reported that there are 3 JNK members with 10 alternatively spliced isoforms that are very similar but dier in interaction with ATF2, Elk-1 and Jun transcription factors (Gupta et al., 1996) . Since a previous study had identi®ed only one stress-activated protein kinase (45 kD (Milne et al., 1995) ; however, its speci®c protein kinase has not been de®nitively identi®ed. It is necessary to con®rm whether JNK1 is indeed the p53 serine 34 kinase and the sole protein kinase which phosphorylates this site for two reasons. First, exposure of mammalian cells to u.v. irradiation stimulates transcription factors AP-1, NF-kB and activates several protein kinases (for review, see Herrlich et al., 1992) , among which JNK1 and JNK2 are rapidly and potently activated (Devary et al., 1993; Hibi et al., 1993) . It is possible that some novel u.v.-induced protein kinases can act on both cJun and p53, and be inhibited by the tyrosinethreonine dual speci®city protein phosphatase CL100 (Milne et al., 1995; Alessi et al., 1993) . Second, c-Fos can associate with c-Jun to form stable AP-1 (c-Jun/cFos) heterodimers and a c-Fos regulating kinase (FRK) can phosphorylate c-Fos and work together with JNK1 to augment AP-1 activity (for review, see Karin, 1995) . It is possible that some novel c-Fos protein kinases may associate with JNK1 in the complex of c-Jun/c-Fos and be responsible for phosphorylation of p53 serine 34. Thus, the most de®nitive veri®cation of this p53 kinase is to examine JNK1 kinase activity on p53 and its association with p53.
Very recently, we have identi®ed and cloned a novel protein kinase, termed hematopoietic progenitor kinase 1 (HPK1), that can potently activate JNK1 signaling pathway (Hu et al., 1996) . Although the function of JNK2 or JNK3 seems to be similar to that of JNK1, it is not clear whether JNK2 or JNK3 can be activated by HPK1. Our data indicate that JNK2 and JNK3 can both be activated by HPK1, albeit activation of JNK3 by HPK1 is weaker than that of JNK1 or JNK2. It has been previously shown that all JNK isoforms can be stimulated by proin¯ammatory cytokine interleukin-1 (Gupta et al., 1996) . Furthermore, we show that JNK1, JNK2 and JNK3 can be activated by the same activators tested (anisomycin, MEKK1 and HPK1), suggesting that all JNK members are regulated by the same signaling pathway.
Identifying the phosphorylation events that cause changes in p53 conformation and function is important in understanding how the cell detects and responds to environmental stress or apoptotic agents. While phosphorylation of serine 34 of mouse p53 is likely to be physiological (Milne et al., 1995) , the functional role of this post-translational modi®cation is still unknown and remains to be elucidated. One interesting hypothesis is that phosphorylation of serine 34 of p53 by JNKs may play a crucial role in p53-induced apoptosis because (1) both JNKs and p53 are activated by u.v. irradiation and (2) it has been recently reported that sustained activation of JNK1 induces apoptosis (Xia et Chen et al., 1996; Verheij et al., 1996) . Little is known about the mechanisms governing the control of p53-or JNK1-induced apoptosis. Establishing JNKs as p53 kinases may open a new avenue for investigating apoptosis associated with p53 and JNK. For example, overexpression of wild-type p53 in cell lines derived from JNK-knock out mice might only induce growth arrest but no apoptosis. Future experiments might bring the p53-dependent apoptosis pathway together with the JNK1-induced apoptosis pathway.
Materials and methods
Plasmids, antibodies, and proteins JNK1 cDNA expression vector (pCI-JNK1) was constructed as previously described (Hu et al., 1996) . The HA-tagged JNK2 cDNA was obtained from a human leukocyte cDNA library (Clontech, Inc.) by the PCR technique using oligonucleotides 5'-TCTAGAGTCGA-CGCCA CCATG TA CCCATACGATGTTCCG GATTAC-GCTAGCCTCAG CGAC AGTAAATGT GACAGTCAG-TTT-3' and 5'-TATTGCGGCCGCTTATCATCGACAG-CC TTCAAGG G GTCC-3' as primers to incorporate a HA epitope (Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-SerLeu) at the N-terminus of JNK2. The PCR generated product was cloned into the expression vector pCI-neo (Promega, Inc.), and designated pCI-HA-JNK2. Similarly, the HA-tagged JNK3a1 cDNA was initially obtained from a human brain cDNA library (Clontech, Inc.) by the PCR technique using oligonucleotides 5' -TCTAGAGTC-GACGCCACCATGT ACCCATAGATGTT CCGGATTA-CGC TAG CCTCA GCCTC CATTTC T TATACTACTGC-AGTG -3' and 5' -TAT TG CGG CCG CT TAT CACTGC-TGCACCTGTG CT GAAGGAG -3' as primers to incorporate a HA tag at the N-terminus of JNK3a1. This PCR generated product was cloned into the expression vector pCI-neo, and designated pCI-HA-JNK3. Subsequently, the FLAG-tagged JNK3a1 cDNA was obtained by PCR technique using pCI-HA-JNK3 as the template and oligonucleotides 5'-TCTAGAGTCGACGC CACCAT-GAGCCTCCATTTCTTATACTACT GCAG -3' and 5'-TATTGCGGCCGCT TATCATTTATCATCATCA TCTT-TAT AA TC C TGCTGC ACC TGTGCTG AAG G AGAA-G G-3' as primers to incorporate a FLAG epitope (AspTyr-Lys-Asp-Asp-Asp-Asp-Lys) at the C-terminus of JNK3a1 and delete the HA tag at the N-terminus. The JNK3a1-FLAG cDNA was cloned into the expression vector pCI-neo, designated pCI-JNK3-FLAG. The sequences of these cDNA constructs were con®rmed by DNA sequencing on both strands using a PCR procedure employing¯uorescent dideoxynucleotides and a model 373A automated sequencer (Applied Biosystems). HPK1 cDNA (Hu et al., 1996) was cloned into the expression vector pCI-neo between the NheI and NotI sites, designated pCI-HPK1. A c-Rel expression plasmid pRcCMV-cRel was kindly provided by Dr Tse-Hua Tan (Baylor College of Medicine, USA). A full-length p53 expression plasmid pCMV-p53 was obtained from Dr Sushil Thukral (Amgen, Inc.). E. coli expression constructs GST-p53(FP221) and GST-p53(FP274) were previously described (Milne et al., 1995) and kindly provided by Dr David Meek (U Dundee, United Kingdom). The GST-c-Jun(1 ± 193), pCI-HA-MEKK1, pC3-JNK(APF), and pVA1 (containing the adenovirus VA1 RNA gene) plasmids were constructed or obtained as previously described (Hu et al., 1996) . Polyclonal antisera were raised against synthetic peptides of human JNK1 (Chen et al., 1996) or HPK1 in rabbits as described (Hu et al., 1996) . Anti-HA monoclonal antibody HA.11 (16B12) and anti-FLAG monoclonal antibody M2 were purchased from Berkeley Antibody Co. and Kodak Scienti®c Imaging Systems, respectively. Anti-p53 monoclonal antibody (DO-1), the horseradish peroxidase-conjugated anti-p53 monoclonal antibody and the full-length p53 protein (1 ± 393) were purchased from Santa Cruz Biotechnology. Anti-c-Rel antiserum was purchased from Upstate Biotechnology. All GST-fusion proteins were puri®ed by anity chromatography on Glutathione Sepharose 4B (Pharmacia Inc.) according to the manufacturer's instructions.
Cell culture and transfections
293T cells were grown in Dulbecco's modi®ed Eagle's (DME) medium supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Inc.). Cells to be transfected were plated the day before transfection at a density of 2610 6 cells per 100 mm dish. 293T cells were cotransfected with expression plasmids (10 mg each plasmid per dish) as indicated without or with pVA1 (10 mg per dish) to enhance transient protein expression, using the calcium phosphate precipitation protocol (Specialty Media, Inc.). For anisomycin stimulation, 293T cells were starved in DME medium containing 1% FBS for 16 h, then treated with anisomycin (1 mg/ml) for 1 h.
Immunoprecipitation and Western blot analysis
Cells were lysed in WCE lysis buer (20 mM HEPES, pH 7.4, 2 mM EGTA, 50 mM b-glycerophosphate, 1% Triton X-100, 10% glycerol, 1 mM DTT, 2 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mM Pefabloc (Boehringer Mannheim) or PMSF, 1 mM sodium othovanadate). Soluble lysates were prepared by centrifugation at 10 000 g for 30 min at 48C. The lysates were precleared using Pansorbin cells (Calbiochem) and then incubated with speci®c antibodies. After 16 h of incubation, immunocomplexes were recovered with the aid of Gamma-Bind Sepharose beads (Pharmacia, Inc.) and then washed four times with lysis buer. Subsequently, immunoprecipitates were analysed by Western blotting after SDS ± PAGE (10%), electroblotted onto PVDF membranes (Novex, Inc.), and probed with the corresponding rabbit antiserum or mouse monoclonal antibody. Immunocomplexes were visualized by enhanced chemiluminescence (ECL) detection (Amersham) using goat antirabbit or anti-mouse antisera conjugated to horseradish peroxidase as a secondary antibody (PIERCE).
Double-cycle immunoprecipitation
A double-cycle immunoprecipitation was performed to dissociate the protein-protein complexes as described (Bryan et al., 1994) with some modi®cations. After transfection 293T cells were starved for 1 h at 378C in labeling medium (methionine-and cysteine-free DME medium containing 2% dialyzed FBS and 1 mM bmercaptoethanol), then incubated for 12 h at 378C in 2 ml labeling medium containing [
35 S]methionine and [ 35 S]cysteine (Amersham) (each at 100 mCi/ml). Cell lysates were prepared as described above except that cells were lysed in RIPA buer (20 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EGTA, 1% Nonidet P-40, 1% deoxycholate, 0.15% SDS, 5% glycerol, 2 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mM Pefabloc). The lysates were precleared using Pansorbin cells (Calbiochem) and then incubated with anti-JNK1 antiserum. After 16 h of incubation at 48C, immunocomplexes were recovered with the aid of GammaBind Sepharose beads and then washed four times with NDS buer (0.5% Nonidet P-40, 0.1% deoxycholate, 0.1% SDS, 2 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mM Pefabloc, 10 mM NaF, 1 mM Na 3 VO 4 ). The washed precipitates were resuspended in 50 ml disruption buer (125 mM Tris-Cl, pH 7.5, 150 mM NaCl, 3% SDS, 5% b-mercaptoethanol) and boiled for 5 min. The supernatant of the boiled sample was collected, diluted to 1 ml with RIPA buer, and precipitated again for 16 h at 48C with anti-p53 monoclonal antibody and Gamma-Bind Sepharose beads as before. These double-cycle immunoprecipitates were then subjected to SDS-PAGE (10%). The polyacrylamide gel was treated with AMPLIFY (Amersham) for 15 min, dried under a vacuum, and exposed to a ®lm for *20 ± 30 days
Immunocomplex kinase assays
Immunocomplex kinase assays were carried out as described (Kyriakis et al., 1992) with some modi®cations. Cellular JNK1 or JNK2 or JNK3 proteins were immunoprecipitated by incubation with rabbit anti-JNK1 or anti-HPK1 antisera or anti-HA or anti-FLAG monoclonal antibodies and protein A-agarose beads (Bio-rad) in WCE lysis buer. After 3 h of incubation at 48C, the immunoprecipitates were collected and washed twice with WCE lysis buer, twice with LiCl buer (500 mM LiCl, 100 mM Tris-Cl, pH ± 7.6 and 0.1% Triton X-100) and twice with kinase buer (20 mM Mops, pH 7.6, 2 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, 0.1% Triton X-100, and 1 mM Na 3 VO 4 ). Pellets were then mixed with 5 mg of substrate, 20 mCi of [g-32 P]ATP and 15 mM of unlabeled ATP in 30 ml of kinase buer. The substrates included GST-p53(FP221), , and GST-c-Jun(1 ± 193). The kinase reaction was performed for 30 min at 308C and terminated by boiling in an equal volume of Laemini sample buer, and the products were resolved by SDS ± PAGE (10%). The gel was dried and subjected to autoradiography.
In-gel kinase assays
The assays were performed by using the procedures of Kameshita and Fujisawa (1989) with some modi®cations. Proteins precipitated by anti-JNK1 antiserum and protein A-agarose beads (Bio-Rad) or Pansorbin cells (Calbiochem) were analysed by SDS ± PAGE (10%) copolymerized with 40 mg/ml GST-p53(FP22) or GST-p53(FP274). After electrophoresis, SDS was removed by incubation in 200 ml of 20% isopropanol in 50 mM Tris-Cl (pH 8.0) for 1 h, followed by 1 h in 200 ml of 5 mM DTT in 50 mM Tris-Cl (pH 8.0). To denature the proteins, the gel was incubated in 80 ml of 6 M guanidine hydrochloride, 5 mM DTT, 50 mM Tris-Cl (pH 8.0) for 1 h, twice. The proteins were renatured by incubation in 200 ml of 0.04% Tween 20, 1 mM DTT, 50 mM Tris-Cl (pH 8.0) at 48C without agitation, during which time the incubation buer was changed every 3 h for 16 ± 18 h. For the kinase reaction, the gel was equilibrated in 15 ml of kinase buer (20m mM HEPES, pH 7.6, 20 mM MgCl 2 , 20 mM b-glycerophosphate, 0.1 mM Na 3 VO 4 2 mM DTT, 20 mM p-nitrophenylphosphate) for 30 ± 60 min at 48C. The kinase reaction was carried out in 15 ml of the same buer containing 150 mCi of [g-32 P]ATP and 50 mM of ATP for 60 min at 308C. The gel was washed extensively with 5%(w/v) trichloroacetic acid plus 1% sodium pyrophosphate until the washes were free of radioactivity. The gel was dried and subjected to autoradiography.
Phosphoamino acid analysis
The phosphorylated proteins obtained from Immunocomplex kinase assays were transferred electrophoretically to PVDF membranes. The spots containing phosphoproteins on the membranes were excised according to the bands on autoradiograms, and then hydrolyzed in 50 ml 6 N HCl for 1 h at 1108C. The supernatant was lyophilized and dissolved in 6 ml pH 1.9 buer (2.2% formic acid and 7.8% acetic acid) containing cold phosphoamino acids as markers. The phosphoamino acids were resolved electrophoretically in two dimensions using a thin-layer cellulose (TLC) plate with two pH systems as described (Boyle et al., 1991) . The markers were visualized by staining with 0.2% ninhydrin in acetone and the 32 P-labeled residues were detected by autoradiography.
